Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
OHSU Knight Cancer Institute
British Columbia Cancer Agency
Mayo Clinic
City of Hope Medical Center
University of California, San Francisco
Mayo Clinic
Thomas Jefferson University
Assistance Publique - Hôpitaux de Paris
M.D. Anderson Cancer Center
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Augusta University
Augusta University
UNICANCER
Mayo Clinic
Beijing Tiantan Hospital
Eastern Cooperative Oncology Group
Mayo Clinic
Mayo Clinic
University Hospital, Angers
Centre Leon Berard
European Organisation for Research and Treatment of Cancer - EORTC
Ohio State University Comprehensive Cancer Center
CHU de Reims
Assistance Publique Hopitaux De Marseille
University Hospital, Toulouse